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Distribution of Naive and Memory/Effector CD4+ T Lymphocytes and Expression
of CD38 on CD8+ T Lymphocytes in AIDS Patients With Tuberculosis
Denise do Socorro S. Rodrigues, Rosangela M. de C. Cunha, Division of Infectious Diseases, Federal
Esper Georges Kallas and Reinaldo Salomao University of São Paulo, São Paulo/SP, Brazil
CD4+ and CD8+ T lymphocyte counts, naive and memory/effector CD4+ T subpopulations, and
the expression of CD38 on CD8+ T lymphocytes were evaluated in four groups: AIDS patients with
tuberculosis (HIV/TB, n=14), HIV-1 infected patients (HIV, n=10), HIV-1 negative patients with
tuberculosis (TB, n=20) and healthy controls (CTL, n=17). TB and HIV had fewer CD4+ T cells
than CTL, with the lowest values observed in TB/HIV (p<0.001). No difference between groups
was observed in the percentage of naive and memory/effector subpopulations in CD4+ T  lymphocytes.
TB (355 cells/µL) and HIV (517 cells/µL) had diverging effects on CD8+ T cell counts, with a
marked depletion observed in HIV/TB (196 cells/µL). TB and HIV up-regulated CD38 expression
on CD8+ T cells, a finding also present in TB/HIV. While the decrease of CD4+ T cell counts in
HIV/TB may be attributed to HIV and tuberculosis, the decrease of CD8+ T cell counts is likely to
be due to tuberculosis.
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Since the 90’s, the global burden of tuberculosis
(TB) has been markedly influenced by the acquired
immunodeficiency syndrome (AIDS) epidemic. HIV
infection has been claimed as one of leading causes of
the recrudescence of tuberculosis in developed
countries. Likewise, an increasing proportion of
tuberculosis is occurring in HIV-infected patients
worldwide [1].
Co-infection with Mycobacterium tuberculosis
and HIV leads to alteration in the clinical course of
both diseases [2,3]. It has been demonstrated that HIV-
infected persons have a much higher susceptibility to
M. tuberculosis disease. Clinical manifestations of
tuberculosis in HIV-patients are usually more severe,
with diffuse pulmonary involvement, and frequent extra-
pulmonary dissemination [4]. In addition, M.
tuberculosis has been shown to increase HIV-1
replication [5,6], and possibly progression to AIDS
[7,8].
Thus, it is conceivable that the immune derangement
found in co-infected patients differs from that of patients
infected with either of these pathogens alone. It has
been shown that co-infected patients have decreased
proliferative response to M. tuberculosis antigens, and
reduced production of IL-2 and IFNγ, compared to
patients with tuberculosis and no HIV [8].
T lymphocytes play a pivotal role in host responses
to M. tuberculosis and HIV-1 infections.
Immunophenotyping of peripheral T lymphocytes and
expression of surface activation markers in HIV-
infected patients has demonstrated an imbalance of
naive and memory/effector cells on CD4+ cells [9] and
enhanced expression of activation surface markers, such
as CD38, on the CD8+ cells [10]. We have recently
shown how M. tuberculosis infection and disease affect
these parameters [11]. However, there is little
information on these parameters in patients co-infected
with M. tuberculosis and HIV-1. Most investigations
conducted on patients with both M. tuberculosis and
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HIV-1 fail to estimate the contribution of each infection
per se in the immune derangement seen in co-infected
patients. We evaluated CD4+ and CD8+ T cell counts,
the CD4+ T lymphocytes subpopulations of naive and
memory/effector cells, and the expression of CD38, a
surface activation marker, on CD8+ T lymphocytes in
patients co-infected with both M. tuberculosis and HIV
and in patients infected either with M. tuberculosis or
HIV.
Materials and Methods
Patients and Healthy Volunteers. Institutional Review
Board approved written informed consent was
obtained from all participants, according to the Brazilian
Ministry of Health Guidelines. Four groups of volunteers
were enrolled: (1) the active TB group consisted of
HIV-1 negative patients with recently diagnosed active
pulmonary tuberculosis, defined by a medical history
and clinical findings compatible with pulmonary
tuberculosis, a thoracic roentgenogram showing lung
involvement suggestive of tuberculosis, and isolation
of M. tuberculosis from a respiratory tract specimen;
(2) the asymptomatic HIV group consisted of HIV-1-
infected individuals, as determined by an enzyme-linked
immunosorbent assay (ELISA) and a confirmatory
Western Blot or Indirect Immunofluorescence assay.
All patients had CD4 T lymphocyte counts of less than
350 cells/µL) and had no evidence of active opportunist
disease; (3) the co-infected group consisted of HIV-
1-infected patients who presented with tuberculosis,
based on clinical and laboratory findings, as defined
above, enrolled prior to tuberculosis treatment; (4) the
control group consisted of healthy volunteers, who had
two consecutive non-detectable delayed-type
hypersensitivity intradermal reactions to a purified
protein derivative, and had no evidence of active
respiratory disease.
Monoclonal Antibodies and Sample Preparation. CD27
phycoerythrin (PE, clone L128), CD45RA FITC (clone
L48), CD8 peridin chlorophyll protein (PerCP, clone
SK1), CD4 PerCP (clone SK3), and CD3
allophycocyanin (APC, clone UCHT1) monoclonal
antibodies were obtained from Becton Dickinson
Immunocytometry Systems (BDIS, San Jose, CA), and
CD38 FITC (clone HIT2) was obtained from
Pharmingen (San Diego, CA). One hundred microliters
of EDTA-treated blood were incubated at room
temperature with a combination of monoclonal
antibodies for 15 minutes in the dark, and then treated
with hemolysis buffer for a further 10 minutes. Cells
were washed and resuspended in phosphate saline
buffer supplemented with 0.1% sodium azide for
cytometric analysis. Cell samples were analyzed on a
FACSCalibur flow cytometer (BDIS). The
subpopulation of naive (as defined by CD45RA+/CD27+)
and effector/memory cells (CD45RA-) was analyzed as
the percentage of cells expressing these surface markers
on the CD4+ T lymphocytes. The activation of CD8+ T
lymphocytes was determined by the percentage of
expression of CD38, after establishing the quadrants in
samples with fluorescence labeled isotype control
antibodies. For blood T CD4+ and CD8+ lymphocyte
absolute counts, a TriTest and TrueCount reagent kit
(BDIS) was used according to the manufacturer’s
instructions. Samples were acquired and analyzed using
Multiset and CellQuest software (BDIS).
Statistical Analysis. Statistical analysis used Statistica
(StatSoft, Tulsa, OK, USA) and NCSS (Keysville,
UT, USA) software. Group results were compared
using a Kruskal-Wallis one way ANOVA on ranks test.
For those variables identified as having a p<0.05,
multiple pair-wise group comparisons were further
performed, using a Z value calculated with the
Bonferroni correction as a threshold for statistical
significance.
Results
From August, 1999, to July, 2000, 61 subjects were
enrolled in the four defined groups: active TB (n=20),
asymptomatic HIV+ group (n=10), co-infected group
(n=14), and healthy volunteers group (n=17). Age in
years (mean± standard deviation) was nearly the same
in the four groups (33±11, 30±6, 29±6 and 32±13,
respectively).
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Figure 1. Peripheral blood numbers of CD4+ T lymphocytes in co-infected, asymptomatic HIV+ patients (HIV+),
active tuberculosis (TB) and healthy volunteers. Box plot represents the median, 25th/75th percentile and extreme
values. Figure 1A represents the absolute peripheral blood numbers of CD4+ T lymphocytes and Figure 1B shows
the percentage participation of the naive subpopulation (CD45RA+/CD27+) among T CD4+ cells. Significant
differences between groups was observed in CD4+ T counts in all pairwise comparisons, except between co-
infected and the HIV+ asymptomatic group.
*p<0.05 compared to TB and healthy volunteers.
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Figure 2. Peripheral blood CD8+ T lymphocytes in co-infected, asymptomatic HIV+ patients (HIV+), active
tuberculosis (TB) and healthy volunteers. Box plot represents the median, 25th/75th percentile and extreme
values. Figure 2A represents the absolute peripheral blood numbers of CD8+ T lymphocytes and Figure 2B
shows the percentage of CD8+ T lymphocytes expressing CD38.
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CD4+ T lymphocyte counts were significantly
different among the four groups (p<0.001), with the
highest cell counts in the healthy volunteers (median
1,153 cells/µL, range 715 to 2,218 cells/µL), and the
lowest in HIV/TB patients (median 53.5 cells/µL, range
2 to 194 cells/µL). According to multiple-comparison
analyses by the Bonferroni test, the CD4 T cell counts
were higher in TB patients (median 690 cells/µL, range
291 to 1,124 cells/µL) than in the HIV asymptomatic
(median 178 cells/µL, range 38 to 262 cells/µL) and
HIV/TB patients (Figure 1A). The percentage of CD4+
T lymphocyte subpopulations of naive cells did not
differ among the groups (p=0.76), nor did memory/
effector subpopulations (p=0.67) (Figure 1B).
The number of CD8+ T lymphocytes was significantly
different among the four groups (p<0.001). TB and
HIV infection exerted differential effects on CD8+ T
cell counts (median 355 cells/µL, range 138 to 917
cells/µL, and 517 cells/µL, range 438 to 1,108 cells/
µL respectively), with co-infection resulting in a marked
depression of these cells (median 196 cells/µL, range
10 to 1,009 cells/µL) (Figure 2A).
The percentage of T CD8 expressing CD38 was
different among the four groups (p=<0.001), with the
lowest values presented by the healthy volunteers
(Figure 2B). Asymptomatic HIV-1 patients had higher
expression than tuberculosis patients, and HIV/TB
patients were similar to asymptomatic HIV-1 patients,
but had a higher expression than TB-patients (p<0.05).
Discussion
HIV-infected patients with tuberculosis had lower
CD4+ and CD8+ T lymphocytes counts than patients
with single TB or HIV infections, respectively. Both
HIV-infected and TB patients presented lower CD4+
T lymphocyte counts than healthy controls. Low CD4+
T cell counts was an inclusion criterion for HIV patients
(less than 350 cells/µL). This criterion, along with a lack
of an ongoing opportunistic infection and antiretroviral
therapy, was designed to enroll asymptomatic HIV-
patients with established HIV-induced immune
alterations. It is not unexpected that HIV-patients with
opportunistic infections have lower CD4+ T cell counts
than asymptomatic patients. Thus, the tendency towards
lower cell numbers seen in co-infected patients may reflect
more advanced HIV disease in such individuals.
However, one may consider a role for TB as a further
factor for the decrease of T CD4+ lymphocytes in such
susceptible patients. This makes sense when we examine
the depression of CD4+ T lymphocyte counts found in
the group of patients with tuberculosis and not infected
by HIV [11].
The decrease of CD4+ T lymphocytes was found to
be differentially distributed in naive, memory and effector
subpopulations, with the differences in absolute cell
numbers in each subpopulation reflecting what was
observed in total T CD4+ cells (data not shown). Although
one may expect a change in the distribution of these
subpopulations in the HIV/TB setting, as well as in each
disease independently, we did not find differences in this
study, which may be due to the small numbers of subjects
in each group. A decrease in naive CD4+ cells has been
described in HIV-infected patients with advanced disease
[9]. We recently evaluated CD4+ T cell subpopulations
in persons with TB infection (PPD positive skin test)
and patients with disease, before and after treatment,
and found a major impact on T CD4+ cells, but again
changes in the percentages of naive and memory/effector
cells were not significantly different [11].
We found that TB and HIV infection have different
effects on CD8+ T cell counts. In TB patients there was
a decreased number of CD8+ T lymphocytes, while the
cell numbers were not altered in HIV-infected patients.
In general these cells are found in enhanced numbers
in HIV-infected patients during long periods of the
natural progression of HIV infection [12]. The
occurrence of TB in AIDS patients results in a strong
reduction of CD8+ T lymphocytes, compared to HIV-
infection alone, with a trend towards absolute counts
even lower than in patients with tuberculosis. This
finding, coupled with the extremely low CD4+ T cell
counts, may contribute to the impaired cellular immunity
seen in co-infected patients.
Expression of CD38 on CD8+ T lymphocytes is a
useful tool to evaluate the state of cellular activation,
which is higher in HIV-infected patients than in negative
controls, increases as the disease advances, and has
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been shown to be a predictor of progression of this
disease [13]. We have previously reported enhanced
expression of CD38 in patients with TB, compared to
treated patients [11]. Our results support the hypothesis
of augmented expression of CD38 secondary to HIV
infection, at a proportion as high as 89% of CD8+T
lymphocytes expressing CD38 in HIV/TB patients,
demonstrating the high state of activation of these cells.
Thus, whereas HIV/TB resulted in a decrease of CD8+
T cell counts, the marked upregulation of CD38 remains
as high as in HIV-infected patients, as a result of both
HIV infection and TB.
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